Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

3,138

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Vaccine

surface antigen, inactivated, prepared in cell cultures

BIOLOGICAL

Influenza Vaccine

surface antigen, inactivated, prepared in egg (influvac ®)

BIOLOGICAL

Influenza Vaccine

surface antigen, inactivated, prepared in cell cultures

BIOLOGICAL

Influenza Vaccine

surface antigen, inactivated, prepared in cell cultures

Trial Locations (19)

1150

Site Reference ID/Investigator# 44656, Grafton

2035

Site Reference ID/Investigator# 44648, Maroubra Junction

2077

Site Reference ID/Investigator# 44663, Hornsby

2148

Site Reference ID/Investigator# 44651, Blacktown

Site Reference ID/Investigator# 44659, Blacktown

2292

Site Reference ID/Investigator# 44647, Broadmeadow

3010

Site Reference ID/Investigator# 44655, Rotorua

3110

Site Reference ID/Investigator# 44654, Tauranga

3145

Site Reference ID/Investigator# 44644, Malvern East

4006

Site Reference ID/Investigator# 44650, Herston

4020

Site Reference ID/Investigator# 44645, Kippa-Ring

4066

Site Reference ID/Investigator# 44662, Auchenflower

4075

Site Reference ID/Investigator# 44643, Sherwood

4152

Site Reference ID/Investigator# 44646, Carina Heights

4510

Site Reference ID/Investigator# 44649, Caboolture

5000

Site Reference ID/Investigator# 44652, Adelaide

6035

Site Reference ID/Investigator# 44657, Wellington

9012

Site Reference ID/Investigator# 44658, Dunedin

Unknown

Site Reference ID/Investigator# 44653, Christchurch

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Abbott Biologicals

INDUSTRY

NCT00999206 - Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine | Biotech Hunter | Biotech Hunter